Tirzepatide

The Uncomfortable Truth About Ozempic

Kurzgesagt – In a Nutshell

GLP-1/GIP dual agonist (tirzepatide); described in the video as a powerful weight-loss/diabetes drug (brand mention in transcript as tzepatite).

How Sugar & Processed Foods Impact Your Health | Dr. Robert Lustig

Andrew Huberman

A dual GLP-1/GIP receptor agonist from Eli Lilly, marketed as Mounjaro (diabetes) and Zepbound (obesity), shown to be slightly more effective for weight loss.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

The active drug in Mounjaro and Zepbound, a dual agonist for GLP-1 and GIP receptors, leading to substantial weight loss.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A GLP-1/GIP dual agonist drug, marketed as Mounjaro for diabetes and Zepbound for obesity, which is more effective than semaglutide with fewer side effects.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

A co-agonist drug that acts on both GLP-1 and GIP receptors, known by the brand name Mounjaro, showing promising results for weight loss.

The Ozempic Expert: Ozempic Transforms Your Gut Microbiome! People Are Being Overdosed On Ozempic!

The Diary Of A CEO

Dr. Mehmet Oz on Fixing American Healthcare + Fraud | Live from Davos

All-In Podcast

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD

Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Andrew Huberman

Referred to as semaglutide version 2.0, primarily used for type 2 diabetics and for weight loss. Dr. Koniver uses compounded micro-dosages to mitigate muscle loss.

252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting

Peter Attia MD

A GLP-1 agonist, mentioned as a drug for weight loss, with concerns about its use for minor weight loss and potential for muscle wasting if protein intake is not maintained.

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A new dual agonist (GIP and GLP-1 receptor agonist) approved for diabetes with dramatic weight loss effects (up to 50 pounds), but cardiovascular outcome trials for diabetes are ongoing, and not yet FDA approved for weight management.

AI Expert Warns: “This Is The Last Mistake We’ll Ever Make” - Tristan Harris

Chris Williamson

A pharmaceutical drug, mentioned as an 'artificial solution to an artificial food landscape,' drawing a parallel to AI as an artificial solution to problems created by technology.